Abstract 3854
Background
The aim of this study is to determine the palliative care needs of cancer patients and to examine the knowledge and expectations of the patients and their families about palliative care.
Methods
The research was conducted as a descriptive study.The sampling has formed 110 patients and 110 patients families who received a treatment between the dates of June- August 2017. The datas were collected for using socio-demographic and palliative care survey and questionnaire form, Palliative Performance Scale and Edmonton Symptom Scale.
Results
80.9% of the patients have received information about the disease. 76.4% of the patients and 60% their families weren’t aware of palliative/supportive care, and 49.1% of the patient/55.5% of the family have been seen worries and expectations for treatment and care. These anxieties of in the patients 46.4% can’t be like former ones and 31.8% have got a pain, while the anxieties of in the patients families 43.6% were losing their patients life and 33.6% is the extension of the treatments period. 63.6% of the families had problems with maintaining their daily work. 25% of the patients defined palliative care as end-of-life care, while others patients defined it as a symptom management and supportive treatment. Expectations of 99.1% the patients and 97.3% of their families were to learn the treatment and care plan; 97.3% of the patients and 80% of the families were to be included and supported in the decisions taken; 97.3% of patients and 97.3 of the families were to be informed about cost of treatment-care; in the treatment process 77.3% of the patients / 85.5% of the families were wants to be supported psychological and, 77.3% of the patients / 50% of the families were want to be supported with receive religious and; 84.5% of the patients / 70% of the families were want to be told the diagnosis.
Conclusions
it has been suggested that patients and their families should be informed about the palliative care, physical, psychosocial, support from the spirütüel direction, while it is proposed to development of tools for determination of their needs and requirements. Key words: Palliative care, Supportive treatment, Cancer, Knowledge and expectation, Patient and patient family.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Özlem Topkaya.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract